<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <STUDY center_name="GEO" alias="GSE179333" accession="SRP326661">
    <IDENTIFIERS>
      <PRIMARY_ID>SRP326661</PRIMARY_ID>
      <EXTERNAL_ID namespace="BioProject" label="primary">PRJNA743296</EXTERNAL_ID>
      <EXTERNAL_ID namespace="GEO">GSE179333</EXTERNAL_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Gene expression changes in REH following STAT3 pharmacological inhibition</STUDY_TITLE>
      <STUDY_TYPE existing_study_type="Transcriptome Analysis"/>
      <STUDY_ABSTRACT>STAT3 (Signal transducer and activator of transcription 3) expression is associated with with t(12;21) acute lymphoblastic leukaemia (ALL) and it is crucial for the survival of the t(12;21) ALL . Our study investigated the STAT3 regulated pathways and discovered a novel STAT3-TP53 axis in B-ALL.  In order to determine the STAT3 regulated pathways in t(12;21) ALL cells, we performed RNAseq analysis on the Pre-B Acute Lymphoblastic Leukemia (ALL) cell line REH, treated with DMSO vehicle control in comparison to 50uM S3I-021, a specific STAT3 inhibitor Overall design: Total cellular RNA was purified from DMSO and 50uM S3I-201 treated REH samples from three independent experiments</STUDY_ABSTRACT>
      <CENTER_PROJECT_NAME>GSE179333</CENTER_PROJECT_NAME>
    </DESCRIPTOR>
    <STUDY_LINKS>
      <STUDY_LINK>
        <XREF_LINK>
          <DB>pubmed</DB>
          <ID>37794795</ID>
        </XREF_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
  </STUDY>
</STUDY_SET>
